Understanding the U.S. Pharmacy Benefit Manager Landscape
Pharmacy benefit managers process over 6.7 billion prescriptions annually in the United States, acting as intermediaries between health plans, pharmacies, and drug manufacturers. While three vertically integrated companies — CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth Group) — control roughly 80%% of claims volume, more than 60 independent and mid-sized PBMs compete for the remaining market.
State Licensing and Regulatory Environment
All 50 states now regulate PBMs, though requirements vary significantly. Most states mandate PBM licensure or registration, with key obligations including:
| Requirement | States Enforcing |
|---|---|
| PBM License or Registration | 40+ |
| Rebate Pass-Through Disclosure | 30+ |
| MAC Appeal Rights for Pharmacies | 45+ |
| Gag Clause Prohibition | All 50 |
Federal Reform: Consolidated Appropriations Act, 2026
Signed into law on February 3, 2026, this landmark legislation requires PBMs to remit 100%% of manufacturer rebates to plan clients and mandates semiannual reporting on drug spending, rebate amounts, and spread pricing arrangements. This fundamentally changes the economics for buyers evaluating PBM partners.
Market Segmentation Beyond the Big Three
- Blue-Affiliated PBMs
- Prime Therapeutics, collectively owned by 19 Blue Cross Blue Shield plans, serves 40M+ members and operates as a group purchasing organization for several smaller PBMs.
- Insurer-Captive PBMs
- CarelonRx (Elevance Health) and Humana Pharmacy Solutions serve their parent companies membership bases, managing formularies for 45M+ and 17M+ lives respectively.
- Independent Pass-Through PBMs
- Companies like Navitus Health Solutions (Costco/SSM Health), Capital Rx, and EmsanaRx differentiate on transparent pricing, claiming 15-20%% cost reductions versus traditional spread-pricing models.
- Specialty and Niche PBMs
- Focused operators manage benefits for workers compensation, 340B entities, hospice, or specific therapeutic areas like oncology and rare disease.
Key Evaluation Criteria for Buyers
When comparing licensed PBMs, benefits directors should focus on:
- Rebate transparency — Does the PBM pass through 100%% of rebates, or retain spread?
- Formulary alignment — How well does the formulary match your populations therapeutic needs?
- Network adequacy — Pharmacy network breadth, including specialty and mail-order coverage
- Accreditation — URAC and NABP accreditation signal operational quality standards
- State compliance — Confirm licensing in every state where your covered population resides